New startup ideas · Health and bio · Healthcare and bio
startup idea
Vitalane
A global marketplace for measuring your own biology, ranked by what actually changes with age.
Vitalane is a consumer app that sells at-home biology panels (blood, saliva, stool, wearable-derived) from independent labs and then sells the follow-on interventions - supplements, sleep and training protocols, coached programs - from vetted vendors in the same checkout.
- Marketplace
- Consumer
- $100B+ market
- Creates a new category
- Global from day one
3/5
venture judge
6
similar startups, last 2 years (60 all-time)
82%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$2,300 · 5 weeks · 25 prospects
For about $2,300 and five weeks, prove that self-pay longevity buyers aged 45-60 will put $50 down on a ranked-measurement bundle and make a second purchase from a hand-run recommendation.
1Focus group: who and where
US adults aged 45-60 who have paid out of pocket for 2 or more blood panels in the past 12 months (Function Health, Marek Health, Quest self-pay or similar) and have bought at least one supplement or protocol because of a result
where to find 25 · Recruit from r/PeterAttia, r/Biohackers and r/longevity via mod-approved posts and comment threads on panel-comparison posts; supplement with a $25-incentive screener on those subreddits asking for a panel receipt as proof
2Sell first, build later
A baseline at-home blood panel with results in 5 days plus a personal ranked plan naming your next measurement and the one intervention most associated with moving your weakest marker, first kits shipping October 5 in Austin and New York
the ask · $199 per bundle, one-time; follow-on products sold at listed vendor prices with Vitalane taking 20%
a real yes · A real yes is a paid $50 deposit or a completed $199 checkout, and for the marketplace thesis a second paid purchase within 14 days of the report. Not a yes: waitlist emails, upvotes, saved posts, or interviewees who praise the report but buy the supplement on Amazon
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Receipt-verified buyer interviews
$450 · 14 days
Run 15 thirty-minute interviews recruited from r/PeterAttia and r/Biohackers, $25 gift card each, admitting only people who show a self-pay panel receipt from the last 12 months. Ask: what did you measure, what did you buy because of it, where did you buy it, what did you measure next and why. Founder runs all interviews.
keep going if · 10 of 15 bought a product or program within 30 days of a panel result and cannot name where they would check whether it worked
2. Priced landing page with deposit
$900 · 21 days
Publish a page selling one concrete bundle: a baseline blood panel plus a ranked what-to-measure-next plan, $199, first kits ship October 5, reserve with a $50 refundable deposit via Stripe Payment Link. Drive $700 of Reddit and Meta ads targeted at longevity and blood-testing interests in two metros, Austin and New York.
keep going if · 15 deposits, or a deposit rate of at least 2% of unique visitors at 750+ visitors
3. Concierge second transaction
$400 · 21 days
For 10 interviewees, take the panel PDF they already have, hand-build a one-page report ranking their next measurement and one specific vendor product tied to their weakest marker, and sell that product through a manual checkout with a 20% margin. No app, no model; a founder and a spreadsheet play the ranking engine.
keep going if · 5 of 10 pay for the recommended product or next panel within 14 days of receiving the report
4. Vendor listing pre-sign
$50 · 14 days
Pitch 10 US supplement, sleep-coaching and training-program vendors found through the products interviewees actually bought. Ask each to sign a one-page listing agreement accepting a 20% take rate and outcome tracking on their SKU, effective at launch. Founder pitches by email and one call each.
keep going if · 6 of 10 sign the listing agreement at 20% with no ad-spend commitment demanded
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$50
per prospect, refundable
how · A $50 refundable reservation via a Stripe Payment Link embedded in the landing page checkout, confirmed by a receipt email restating ship date and locked price set up: Stripe Payment Links ↗
what it reserves · A kit in the October 5 first batch, the $199 price locked, and first access to the ranked follow-on report
refund · Refunded in full anytime before the kit ships, one click from the receipt email
target · 20 deposits within 30 days of the page going live
Go: build it if
20 deposits at $50, 5 of 10 concierge users make a second paid purchase, and 6 vendors signed at a 20% take rate
Kill: stop if
Fewer than 8 deposits from 750+ visitors, or 1 or fewer second purchases from 10 concierge reports, or vendors only sign below a 10% take rate
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
68
Idea Score, 0-100 · raw 41.6 x 1.64
Active
competition: more crowded than 56% of ideas · headwind x0.72
+4.3
government priorities, secondary (66 matching grants)
Trend
58
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)13
- Rounds announced 2025+ in the sector68
- Sector direction (live batch)100
- 2026 trend analyst50
Demand
43
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain0
100x potential
56
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge50
- Market size axis100
- Moat axis80
- Neighbours still alive32
- Technologist judge25
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were global, marketplace, measuring, biology, ranked, changes, consumer, sells.
The idea in full
- What
- Vitalane is a consumer app that sells at-home biology panels (blood, saliva, stool, wearable-derived) from independent labs and then sells the follow-on interventions - supplements, sleep and training protocols, coached programs - from vetted vendors in the same checkout. A multi-omic model trained on the returned panels ranks what each user should measure next and which vendor product moved that marker for people with similar profiles, so the app becomes the default front door for aging-related self-measurement rather than one more test kit. Vitalane runs its own courier and kit-fulfilment operation in five metros so turnaround is days, not weeks, and takes 15-30% of every panel and every product sold through it.
- Why now
- YC's Fall 2026 Requests for Startups names AI for the Aging Population for this cluster, and the S26 batch alone funded Illume Labs (24/7 Personal Health & Longevity Companion) and Gutgutgoose (personalized probiotics), while the radar shows zero crowded pitch phrases across recent companies - demand is being funded but no one owns the consumer transaction layer.
- Wedge: first customer and entry point
- Start with one cohort: people aged 45-60 already buying quarterly blood panels out of pocket. Sell a single subscription panel in two metros, hand-recruit ten supplement and coaching vendors, and take the cut on the second purchase.
- Path to 100x
- Consumer wellness, supplements and self-pay testing is a $100B+ global spend with no ranked, outcome-linked storefront; whoever holds the measurement history holds the recommendation slot for every subsequent purchase. Winner-takes-most comes from distribution: once the app is the default place a vendor reaches self-paying longevity buyers, vendors list here first, and the outcome data from prior panels makes the ranking hard for a second marketplace to copy.
- Ceiling
- Wellness claims stay unregulated only while the company avoids diagnosis, which caps how clinically useful the ranking can be and keeps average order value low.
- Closest real companies, as the generator saw them
- Illume Labs and Optimal sell a single owned companion product; Vitalane sells other people's panels and protocols and keeps the demand. Layers (dead, 2025) tried to own the full 30-minute measurement clinic and carried the capex; the marketplace version does not.
- Main risk
- Consumers churn after two panels because nothing they measure changes how they feel, and the repeat transaction never arrives.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
3/5
Owned courier and kit fulfilment in five metros is ops-heavy, and the stated churn after two panels kills the repeat take rate.
Bootstrapper
2/5
Own courier and kit fulfilment in five metros plus the stated two-panel churn makes repeat revenue the whole business and it is unproven.
Operator
1/5
Self-pay longevity panels are the definition of a vitamin, and the card itself fears churn after two panels because nothing changes.
Technologist
2/5
The multi-omic ranking model sits on other people's panels, and the claimed moat is a 15-30% supplement checkout, not technology.
Risk
1/5
At-home blood and stool panels plus intervention sales are labelled unregulated, ignoring CLIA, state lab rules and FTC health claims exposure.
trends
3/5
Direct Fall 2026 aging RFS fit with an uncrowded transaction layer, yet a wellness marketplace needed no 2025-2026 mechanism and churns on unchanged biomarkers.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (global, marketplace, measuring, biology, ranked, changes, consumer, sells): 60 all-time, 6 from the last two years. Same matching as Idea Check.
Real-time Nielsen ratings for Brands.Accelerate marketing and product…
Shibuya Blend Green Energy is a operator of a carbon trading platform.
Travel Ancillary Marketplace and Management Platform, Powered By AI.
Canovation is revolutionizing the CPG packaging industry with CanReseal®, an all-metal, fully resealable can that is compatible with existing manufacturing and supply chains, offering brands and consumers an all-in-one sustainable packaging solution.
AI native consumer lending platform for underserved Americans
Misprint is building Robinhood for Pokemon cards
Atorie: Luxury Without the Price Tag
Vanta for the consumer goods industry.
Cafler is the leading marketplace for car services online, and an AI- Operating System for mobility companies.
Realizse's mission is to accelerate the world's transition to sustainable products. Realizse is a Web3 platform for the circular economy. Realizse creates verifiable assets with digital twins supporting circularity, sustainability, and traceability for supply chain interoperability.
OS for global e-commerce expansion of brands & manufacturers
Engineering microbes for miners to unlock billions in trapped metal
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1127
startup-relevant grants in Healthcare and bio
$590M
awarded in the sector, tracked
130
opportunities open now in the sector
NIH / NIAMS · SBIR phase I · $313K · posted 2025-08-01
- I-Corps: Translation Potential of an Autonomous Brain-on-a-Chip Platform for Functional Drug Discoveryawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-08-14
National Science Foundation · I-Corps · $50K · posted 2026-08-10
- I-Corps: Translation Potential of Quantum Sensors for Diamond Tool Condition Monitoringawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-08-10
- I-Corps: Translation Potential of an electroacoustic sensing technology using speakers as sensorsawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-08-10
- Clinical Assay to Accurately Profile and Monitor the HIV-1 Reservoir in Chronic-treated Individuals to Guide Treatment Decisionsawardhigh relevance
NIH / NIAID · SBIR phase II · $300K · posted 2026-08-01
- I-Corps: Translation Potential of a Battery Monitoring and Degradation Detection Tool Using Non-Contact Methodsawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-07-29
- SBIR Phase II: Improved Utilization through Artificial Intelligence and Prescriptive Logisticsawardhigh relevance
National Science Foundation · SBIR Phase II · $1M · posted 2026-07-21
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Consumer
- Business model
- Marketplace
- Path to 100x
- Creates a new category
- Market size
- $100B+ market
- Capital intensity
- Capital-medium (ops, field teams)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Self-serve
- Moat
- Distribution moat
- Geography
- Global from day one
- Regulation
- Unregulated
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-22 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.